When a promising ALS drug failed Phase 2 trials, the company shut down. The drug's original founder, Dr. Ari Azhir, still believed in the science, repurchased the asset and all its data, and ultimately uncovered its true potential, leading to a new FDA application.

Extensive diligence on a seed-stage company's market or product is often wasted effort. The majority of successful seed investments pivot to a completely different business model, making the founding team's quality and resilience the most crucial factor to evaluate.

Aphaia's co-founder, a full professor, credits his deep academic connections for the company's success. Being part of the University of Toronto, a hub for GLP-1 research, allowed him to vet his unconventional idea with world-leading experts. This access to high-caliber, informal peer review was critical for making the decision to move forward.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The origin of CNX wasn't a meticulously planned venture. The two co-founders were colleagues who, frustrated with their boss, impulsively quit their jobs together. The company was born out of that moment with no plan and no money, forcing them to be resourceful from day one.

When a biotech company shutters, it's not a total loss. The scientific dead ends it uncovers prevent others from wasting resources on the same path. These "failures" enrich the ecosystem with crucial knowledge and release experienced talent back into the market.

Success isn't linear. Mobile gaming giant Supercell didn't start with mobile games, and drone delivery firm ZipLine began with a robotic toy. This shows that foundational failures in one area can be the necessary learning experiences that lead to market-defining success in another.

Tubulus co-founders decided to launch their company after a single successful experiment, driven by passion rather than a thorough market analysis. This 'healthy naivety' helped them push forward despite industry skepticism towards their antibody-drug conjugate (ADC) technology at the time, which was considered a difficult area.

The co-founders of InflaRx, postdocs from Germany and China, bonded over research at the University of Michigan. Their key scientific discovery about the C5a receptor led to a late-night, beer-fueled conversation where the idea for their company was born, highlighting the role of personal chemistry in innovation.